#Spain #Valencia #ARTHEx Biotech #ATX-01 #gene modulation

ARTHEx Biotech's Participation at the Jefferies Global Healthcare Conference

ARTHEx Biotech S.L., a clinical-stage biotechnology firm based in Valencia, Spain, is poised to highlight its pioneering work in innovative medicines at the upcoming 2025 Jefferies Global Healthcare Conference. The event, which will take place from June 3 to June 5, serves as a significant platform for biotech companies to engage with investors and industry leaders.

About ARTHEx Biotech

Founded with a mission to advance healthcare through gene modulation, ARTHEx Biotech is dedicated to creating cutting-edge therapeutics. The company's focus is on developing innovative medicines that can essentially reshape the future treatment landscape for patients suffering from rare conditions. Currently, ARTHEx is advancing its flagship investigational compound, ATX-01, which is undergoing evaluation in a Phase I-IIa clinical trial called ArthemiR™ for treating myotonic dystrophy type 1 (DM1).

DM1 is a rare neuromuscular disorder characterized by progressive muscle weakness and wasting. As ARTHEx aims to bring ATX-01 to the forefront, it represents not only a significant step for the company but also a beacon of hope for individuals affected by this debilitating condition.

The Upcoming Conference

Frédéric Legros, the Executive Chairman and CEO of ARTHEx Biotech, will lead the company’s participation at the conference, engaging in one-on-one meetings with investors. These discussions will focus on the potential impact of ARTHEx's innovative approach in gene modulation and how it aims to address unmet medical needs in neuromuscular disorders.

Attendance at the Jefferies Global Healthcare Conference provides an invaluable opportunity for ARTHEx to showcase its breakthroughs while also forging meaningful connections with key stakeholders. As biotechnology continues to be instrumental in transforming healthcare solutions, ARTHEx's participation underscores its commitment to advancing scientific research and therapeutic development.

Looking Ahead

As ARTHEx Biotech continues to push boundaries in biotechnology, its participation in events like the Jefferies conference not only enhances its visibility but also reaffirms its dedication to developing effective therapies. The company's innovative discovery engine is also in the works, aimed at identifying microRNA modulators for various disorders, underscoring its position as a leader in the biotechnology sector.

For more information about ARTHEx Biotech and its initiatives, interested parties can visit www.arthexbiotech.com or follow the company on LinkedIn for the latest updates.

ARTHEx Biotech stands at the intersection of innovation and patient care, actively working towards a healthier future for those impacted by significant health challenges.